GENE ONLINE|News &
Opinion
Blog

2021-08-10| IPO

With Increasing Appeal for RNA Technology, Medford Startup Jumps on the SPAC Wagon to Go Public

by Rajaneesh K. Gopinath
Share To

RNA tech firm GreenLight Biosciences Inc. has announced a merger with Environmental Impact Acquisition Corp., a special-purpose acquisition company (SPAC), to go public in a deal worth $1.5 billion. The decision aims to create a joint company that develops products to address two major issues plaguing humankind—human health and food security.

GreenLight’s proprietary, cell-free RNA production technology enables a scalable and safe method to produce fast, cost-efficient RNA. With its groundbreaking tech, the innovative startup has raised a total of $215 million in over 8 funding rounds before announcing the latest merger.

“We are thrilled to partner with Environmental Impact Acquisition Corp. to accelerate our vision and advance the delivery of our solutions to where they are needed most, with shared goals to pave the way for a sustainable planet through widely available and affordable RNA,” said Andrey Zarur, Co-Founder, and CEO of GreenLight Biosciences.

 

RNA-Based Solutions to Global Issues

Headquartered in Medford, Massachusetts, GreenLight Biosciences also has research and development operations in Research Triangle Park in North Carolina. Launched in 2008, the company intends to develop RNA-based sustainable solutions to support human, animal, and plant health.

In addition to utilizing its proprietary messenger RNA (mRNA) production technology to achieve large-scale manufacturing of mRNA vaccines, GreenLight is also working towards finding safe alternatives for pesticides to prevent the killing of beneficial insects. To that end, it is currently developing RNA-based pesticides with the goal of protecting honeybees. In May, it acquired rights to assets of Bayer’s topical RNA Intellectual Property portfolio, which included bee health capabilities.

“We believe that GreenLight’s breakthrough platform can create advanced therapies, vaccines, and crop-protection products that address—quickly, directly, and specifically—some of the most significant problems facing the world today,” said Zarur.

 

A $1.5 Billion SPAC Deal

The SPAC deal valued at $1.5 billion includes a pro forma enterprise value of approximately $1.2 billion for GreenLight upon close. Besides, the transaction will yield $282 million to the company for its operational needs. This includes $105 million in proceeds from a Private Investment in Public Equity (PIPE) transaction priced at $10.00 per share.

The PIPE transaction is supported by S2G Ventures, Cormorant Asset Management, Morningside Venture Investments, Hudson Bay Capital, BNP Paribas Ecosystem Restoration Fund, The Jeremy and Hannelore Grantham Environmental Trust, Continental Grain Company, Pura Vida Investments LLC, Xeraya Capital, and MLS Fund II/Spruce.

“Going public through this partnership will accelerate development and commercialization by enabling us to attract the talent, purchase the tools, scale our manufacturing infrastructure, advance regulatory approvals, and develop further the science necessary to address some of humanity’s most pressing challenges,” Zarur said of the partnership.

The funds from the transaction will provide GreenLight the capital it needs for advancing biopesticides, with the first product expected to launch in 2022. It will also use the money to build the mRNA manufacturing platform that fuels its lead vaccine programs comprising shots for COVID-19 and seasonal flu.

“When considering quality merger partners that aligned with our mission of delivering environmental and social impact, we saw GreenLight as both a notable and compelling partner for ENVI and our shareholders,” said Dan Coyne, CEO of Environmental Impact Acquisition Corp. “We are excited to announce this merger with GreenLight, as there is alignment on how our combined resources may create value for our stakeholders, and how our capital may be invested in a purpose-driven platform committed to improving humanity.”

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
U.S. Government to No Longer Provide Free COVID-19 Vaccines
2022-08-31
Pfizer-BioNTech COVID-19 Vaccine Proven Effective in Young Children
2022-08-23
Pfizer and BioNTech’s New Bivalent Omicron Vaccine Lined Up for Authorization from the FDA
2022-08-22
LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!